Skip to main content
Nykode Therapeutics ASA logo

Nykode Therapeutics ASA — Investor Relations & Filings

Ticker · NYKD ISIN · NO0010714785 LEI · 254900UKQHWYZJD22017 OL Manufacturing
Filings indexed 493 across all filing types
Latest filing 2025-08-27 Regulatory Filings
Country NO Norway
Listing OL NYKD

About Nykode Therapeutics ASA

https://nykode.com/

Nykode Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company's core is its proprietary Vaccibody™ technology, a modular platform designed to create targeted vaccines. This technology works by linking antigens to a targeting unit, which delivers them directly to antigen-presenting cells. This mechanism is engineered to induce rapid, potent, and long-lasting T-cell and antibody immune responses. Nykode's development pipeline is focused on generating therapeutics for a range of diseases, with a primary emphasis on oncology and infectious diseases.

Recent filings

Filing Released Lang Actions
Nykode Announces Updated Strategy to Increase Value for Patients and Shareholders, Prioritizing VB10.16 as the Lead Value Driver
Regulatory Filings Classification · 100% confidence The document is a corporate announcement from Nykode Therapeutics detailing an updated business strategy, pipeline prioritization (specifically VB10.16), and capital allocation. It is a strategic update released via a stock exchange announcement (as indicated by the 'inside information' and 'stock exchange announcement' disclosure at the end). It does not fit the criteria for a full financial report (10-K/IR), a transcript (CT), or a simple report publication notice (RPA), as it contains substantive strategic content. Therefore, it is classified as a general regulatory filing.
2025-08-27 English
Nykode Therapeutics - Quarterly report Q2 2025 - Attachment: 250827 Nykode Quarterly Report Q2 2025.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled '2ND QUARTER 2025 INTERIM REPORT' and contains comprehensive financial statements, including income statements, balance sheet data, and detailed management discussion and analysis (MDA) for the period ending June 30, 2025. It is a substantive financial report rather than a brief announcement or a certification, fitting the definition of an Interim/Quarterly Report. Q2 2025
2025-08-27 English
Nykode Therapeutics - Quarterly report Q2 2025
Report Publication Announcement Classification · 100% confidence The document is a short announcement (under 3,000 characters) that informs stakeholders about the release of the Q2 2025 financial results. It explicitly states that the financial report can be accessed via a link on the company's website and provides details for an upcoming webcast. Per the 'Menu vs Meal' rule, because this is an announcement of a report rather than the full report itself, it is classified as a Report Publication Announcement (RPA).
2025-08-27 English
Nykode Therapeutics – Invitation to Q2 2025 Financial Results Presentation and Strategy Update - Attachment: 250820_Nykode Therapeutics_Q2 2025 Invitation to webcast.pdf
Report Publication Announcement Classification · 100% confidence The document is an announcement regarding the upcoming release of Q2 2025 financial results and an invitation to a webcast presentation. It does not contain the actual financial results or the report itself, but rather informs stakeholders of the date and time of the release. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA).
2025-08-20 English
Nykode Therapeutics – Invitation to Q2 2025 Financial Results Presentation and Strategy Update
Report Publication Announcement Classification · 100% confidence The document is an announcement regarding the upcoming release of Q2 2025 financial results and an invitation to a webcast presentation. It does not contain the actual financial results, but rather informs stakeholders of the date and time of the release and how to access the report once published. Following the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA).
2025-08-20 English
Nykode Therapeutics – Grant of Share Options - Attachment: Attachment 250709.pdf
Director's Dealing Classification · 100% confidence The document text details transactions involving 'persons discharging managerial responsibilities' (executives like CEO, CFO) regarding their holdings or options in the issuer, Nykode Therapeutics ASA. Specifically, it reports the 'Acceptance of a stock option' by multiple insiders. This type of mandatory disclosure concerning personal share transactions by directors and executives is classified as Director's Dealing.
2025-07-09 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.